---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-036740"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2026-08-10T11:15:25+00:00"
generated_at: "2026-08-10T11:20:12.087206+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tonix Q2 2026: TONMYA net sales $11M (+197% QoQ), net loss $40.6M

## Summary
- TONMYA net sales ~$11M, up 197% QoQ; total net product revenue $13.5M vs $2.0M year ago.
- Net loss $40.6M ($2.44/share) vs $28.3M ($3.86/share) in Q2 2025; cash $176.2M at June 30.
- First patient enrolled in Phase 2 HORIZON study of TNX-102 SL for MDD; ~360 patients planned.
- TNX-4800 Phase 2 Lyme prevention study on track to start Q1 2027 pending FDA agreement.
- Sales force to expand to ~150 reps by September; payer coverage ~136M lives (43% U.S.).

## SEC filing metadata
- accession: 0001493152-26-036740
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2026-08-10T11:15:25+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000149315226036740/0001493152-26-036740-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000149315226036740/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-036740
- JSON: https://secwatch.observer/filing/0001493152-26-036740.json
- Plain text: https://secwatch.observer/filing/0001493152-26-036740.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.